Science and Research

Effects of inhaled beclometasone dipropionate/formoterol fumarate/glycopyrronium vs. beclometasone dipropionate/formoterol fumarate and placebo on lung hyperinflation and exercise endurance in chronic obstructive pulmonary disease: a randomised controlled trial

BACKGROUND: The single-inhaler triple combination of beclometasone dipropionate, formoterol fumarate, and glycopyrronium (BDP/FF/G) is available for maintenance therapy of chronic obstructive pulmonary disease (COPD). Cardinal features of COPD are lung hyperinflation and reduced exercise capacity. TRIFORCE aimed to evaluate the effect of BDP/FF/G on lung hyperinflation and exercise capacity in patients with COPD. METHODS: This double-blind, randomised, active- and placebo-controlled, crossover study recruited adults with COPD aged 

  • Watz, H.
  • Kirsten, A. M.
  • Ludwig-Sengpiel, A.
  • Krüll, M.
  • Mroz, R. M.
  • Georges, G.
  • Varoli, G.
  • Charretier, R.
  • Cortellini, M.
  • Vele, A.
  • Galkin, D.

Keywords

  • Humans
  • *Pulmonary Disease, Chronic Obstructive/drug therapy/physiopathology/diagnosis
  • Male
  • *Beclomethasone/administration & dosage
  • Female
  • Double-Blind Method
  • *Glycopyrrolate/administration & dosage
  • *Formoterol Fumarate/administration & dosage
  • Middle Aged
  • *Cross-Over Studies
  • Administration, Inhalation
  • Aged
  • *Exercise Tolerance/drug effects/physiology
  • *Drug Combinations
  • Bronchodilator Agents/administration & dosage
  • Lung/drug effects/physiopathology
  • Treatment Outcome
  • Cycle ergometry
  • Dual bronchodilation
  • Fixed-dose combination
  • Hyperinflation
  • Triple therapy
Publication details
DOI: 10.1186/s12931-024-02993-x
Journal: Respir Res
Pages: 378 
Number: 1
Work Type: Original
Location: ARCN
Disease Area: COPD
Partner / Member: Ghd
Access-Number: 39420338

DZL Engagements

chevron-down